



**PRESS RELEASE
REGULATED INFORMATION**

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), 2nd October 2020, 14:30 (CEST) – In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, **Nyxoaah S.A.** publishes the below information following the issue of 650,250 new shares on 29 September 2020 pursuant to the exercise of the "Over-allotment Warrant" that was conditionally issued on 7 September 2020 and confirmed on 21 September 2020:

- Share capital: EUR 3,792,010.34
- Total number of securities carrying voting rights: 22,074,109 (all ordinary shares)
- Total number of voting rights (= denominator): 22,074,109 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
 - 161 "2013 ESOP Warrants" issued on 3 May 2013 and 23 December 2014, entitling their holders to subscribe for a total number of 80,500 securities carrying voting rights (all ordinary shares);
 - 482 "2016 ESOP Warrants" issued on 3 November 2016, entitling their holders to subscribe for a total number of 241,000 securities carrying voting rights (all ordinary shares);
 - 319 "2018 ESOP Warrants" issued on 12 December 2018, entitling their holders to subscribe for a total number of 159,500 securities carrying voting rights (all ordinary shares); and
 - 550,000 "2020 ESOP Warrants" issued on 21 February 2020, entitling their holders to subscribe for a total number of 550,000 securities carrying voting rights (all ordinary shares).

- ENDS -

For further information, please contact:

Nyxoaah

Rémi Renard, VP Therapy Development and Education

remi.renard@nyxoah.com

+32 472 12 64 40

For media enquiries, please contact:

Consilium Strategic Communications

Amber Fennell, Ashley Tapp, Lindsey Neville, Taiana De Ruyck Soares

Nyxoah@consilium-comms.com

+44 (0)20 3709 5700

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah's lead solution is the Genio[®] system, a CE-validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk¹ and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio[®] system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing ELISA study in Europe to confirm the long-term safety and efficacy of the Genio[®] system.

For more information, please visit www.nyxoah.com.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

¹ Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, *Sleep*. 2008 Aug 1; 31(8): 1071–1078.